Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Astermark

Showing results (61-70 of 92) with videos related to

Pageof 10
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 29, 2021
Treatment outcomes in persons with severe haemophilia B in the Nordic region: The B-NORD studyKristina Kihlberg, Fariba Baghaei, Maria Bruzelius, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 15, 2023
No difference in quality of life between persons with severe haemophilia A and BKristina Kihlberg, Fariba Baghaei, Maria Bruzelius, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 22, 2023
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxisJan Astermark, Tyler W Buckner, Laurent Frenzel, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 3, 2025
Health-Related Quality of Life, Physical Activity and Joint Health in People With Severe Haemophilia A Receiving Emicizumab: Results From the Phase IV HemiNorth 2 StudyJan Astermark, Susanna Ranta, Linda Myrin-Westesson, et al.
Research and Practice in Thrombosis and Haemostasis|January 14, 2025
Nonneutralizing antibodies in Nordic persons with moderate hemophilia A and B (the MoHem study)Ragnhild J Måseide, Erik Berntorp, Jan Astermark, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 7, 2021
Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) studyRagnhild J Måseide, Erik Berntorp, Jan Astermark, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 19, 2025
Evaluation of One-Stage Assays for the Monitoring of Recombinant Human Factor IX Padua Activity After Etranacogene Dezaparvovec Gene TherapyJan Astermark, Wolfgang Miesbach, Michiel Coppens, et al.
Thrombosis Research|July 17, 2022
Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complicationsKristina Kihlberg, Fariba Baghaei, Maria Bruzelius, et al.
Therapeutic Advances in Hematology|October 20, 2023
Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic contextJan Astermark, Fariba Baghaei, Karin Strandberg, et al.
Blood|December 11, 2012
The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined CohortJan Astermark, Sharyne M Donfield, Edward D Gomperts, et al.
Pageof 10

Showing results (61-70 of 92) with videos related to

Sort By:
Pageof 10
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 29, 2021
Treatment outcomes in persons with severe haemophilia B in the Nordic region: The B-NORD studyKristina Kihlberg, Fariba Baghaei, Maria Bruzelius, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 15, 2023
No difference in quality of life between persons with severe haemophilia A and BKristina Kihlberg, Fariba Baghaei, Maria Bruzelius, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 22, 2023
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxisJan Astermark, Tyler W Buckner, Laurent Frenzel, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 3, 2025
Health-Related Quality of Life, Physical Activity and Joint Health in People With Severe Haemophilia A Receiving Emicizumab: Results From the Phase IV HemiNorth 2 StudyJan Astermark, Susanna Ranta, Linda Myrin-Westesson, et al.
Research and Practice in Thrombosis and Haemostasis|January 14, 2025
Nonneutralizing antibodies in Nordic persons with moderate hemophilia A and B (the MoHem study)Ragnhild J Måseide, Erik Berntorp, Jan Astermark, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 7, 2021
Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) studyRagnhild J Måseide, Erik Berntorp, Jan Astermark, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 19, 2025
Evaluation of One-Stage Assays for the Monitoring of Recombinant Human Factor IX Padua Activity After Etranacogene Dezaparvovec Gene TherapyJan Astermark, Wolfgang Miesbach, Michiel Coppens, et al.
Thrombosis Research|July 17, 2022
Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complicationsKristina Kihlberg, Fariba Baghaei, Maria Bruzelius, et al.
Therapeutic Advances in Hematology|October 20, 2023
Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic contextJan Astermark, Fariba Baghaei, Karin Strandberg, et al.
Blood|December 11, 2012
The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined CohortJan Astermark, Sharyne M Donfield, Edward D Gomperts, et al.
Pageof 10